Trials / Completed
CompletedNCT00635284
ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies
A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Celgene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic parameters for ABI-009 when given on a weekly schedule.
Detailed description
No extended description necessary
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-009 | nab-rapamycin |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2011-06-01
- Completion
- 2011-06-01
- First posted
- 2008-03-13
- Last updated
- 2019-10-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00635284. Inclusion in this directory is not an endorsement.